Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05709626

PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction

Conditions: ST-segment Elevation Myocardial Infarction (STEMI)

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE4
Enrollment: 2268
Sponsor: Kindai University

Location: Kindai University Faculty of Medicine Sayama Osaka

Summary

The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).

Eligibility Criteria

Inclusion Criteria: * Patients scheduled for primary PCI with everolimus-eluting stent (PtCr-EES, SYNERGYTM) * STEMI patients * Patients who can continue dual antiplatelet therapy with aspirin and a P2Y12 inhibitor for 12 months Exclusion Criteria: * Patients taking anticoagulants * Patients under 18 years old * Patients with less than 1 year prognosis * Patients participating in other intervention studies

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05709626). StuddyBuddy aggregates publicly available trial information.